Rezolute, Inc. (RZLT)
4.87
+0.23
(+4.96%)
USD |
NASDAQ |
Oct 09, 16:00
4.86
-0.01
(-0.21%)
After-Hours: 20:00
Rezolute Net Income (Quarterly) : -20.49M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.49M |
| March 31, 2026 | -16.17M |
| December 31, 2025 | -22.77M |
| September 30, 2025 | -18.15M |
| June 30, 2025 | -24.39M |
| March 31, 2025 | -18.91M |
| December 31, 2024 | -15.73M |
| September 30, 2024 | -15.38M |
| June 30, 2024 | -22.98M |
| March 31, 2024 | -17.05M |
| December 31, 2023 | -13.91M |
| September 30, 2023 | -14.52M |
| June 30, 2023 | -12.73M |
| March 31, 2023 | -15.67M |
| December 31, 2022 | -13.56M |
| September 30, 2022 | -9.831M |
| June 30, 2022 | -9.423M |
| March 31, 2022 | -11.21M |
| December 31, 2021 | -12.59M |
| September 30, 2021 | -7.836M |
| June 30, 2021 | -6.49M |
| March 31, 2021 | -3.695M |
| December 31, 2020 | -7.097M |
| September 30, 2020 | -3.62M |
| June 30, 2020 | -3.547M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.04M |
| December 31, 2019 | -6.666M |
| September 30, 2019 | -5.08M |
| June 30, 2019 | -3.146M |
| March 31, 2019 | -19.77M |
| December 31, 2018 | -4.161M |
| September 30, 2018 | -3.365M |
| June 30, 2018 | -12.49M |
| March 31, 2018 | -4.968M |
| December 31, 2017 | -5.719M |
| September 30, 2017 | -6.685M |
| June 30, 2017 | -6.189M |
| March 31, 2017 | -5.385M |
| December 31, 2016 | -4.888M |
| September 30, 2016 | -3.816M |
| June 30, 2016 | -3.871M |
| March 31, 2016 | -3.772M |
| December 31, 2015 | -4.066M |
| September 30, 2015 | -3.288M |
| June 30, 2015 | -3.040M |
| March 31, 2015 | -3.173M |
| December 31, 2014 | -2.936M |
| September 30, 2014 | -2.215M |
| June 30, 2014 | -2.005M |
| March 31, 2014 | -5.087M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 3.604B |
| Avalo Therapeutics, Inc. | -36.36M |
| Opus Genetics, Inc. | -8.098M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 20.49M |
| EPS Diluted (Quarterly) | -0.1961 |
| Enterprise Value | 362.63M |
| Earnings Yield | -15.33% |
| Normalized Earnings Yield | -15.40 |